Biogen Shares Rise Despite Tumbled MS Revenue and Forecasted Portfolio Declines
Biogen shares climbed even as its multiple sclerosis drug revenue tumbled, triggering concerns about its core franchise. The company warned of continued portfolio declines driven by patent expirations and increased competition in 2026.
1. Stock Reaction to MS Revenue Drop
Biogen’s stock rose as investors focused on the company’s broader pipeline and cost management, despite a sharp fall in its multiple sclerosis drug revenue. The rally reflects market confidence that new assets and operational efficiencies could partially offset the MS franchise’s underperformance.
2. Outlook for Portfolio Declines
Management forecasts ongoing revenue declines across its portfolio in 2026, citing patent expirations and intensifying competition. The firm is prioritizing late-stage clinical programs and partnership deals to diversify its growth drivers and mitigate risks from legacy assets.